Coronavirus Notebook: EMA Starts Review Of HIPRA’s COVID-19 Vaccine, Moderna To Set Up Australian mRNA Plant
Executive Summary
There is no shortage of news relating to potential new COVID-19 treatments and vaccines. Among other things, zapnometinib, an antiviral compound being developed by German firm Atriva, has shown strong efficacy against Omicron in a Phase I study. Also, Sweden’s ISR and Iconovo have expanded their collaboration deal to accelerate the development of an inhaled COVID-19 vaccine.
You may also be interested in...
EU Boosts COVID-19 Vaccine Supplies With Moderna & HIPRA Deals
New supply arrangements with the two firms are expected to offer greater protection to people in Europe as the autumn/winter season approaches. The EU’s health crisis preparedness body HERA has also identified its “top three health threats.”
EMA: First Adapted COVID-19 Vaccines Expected In September
As work continues on vaccines adapted to tackle variants of SARS-CoV-2, the EU regulator says the decision-making on such products should take place at a global level.
UK To Use Vaccine Taskforce Model For ‘Cutting-Edge’ R&D Funding Program
The latest initiative under the UK’s Life Sciences Vision is intended to fund the development of innovative treatments while saving the National Health Service “millions of pounds.”